Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

William Fantegrossi to Time Factors

This is a "connection" page, showing publications William Fantegrossi has written about Time Factors.

 
Connection Strength
  
 
 
0.490
  
  1. Ford BM, Cabanlong CV, Tai S, Franks LN, Penthala NR, Crooks PA, Prather PL, Fantegrossi WE. Reduced Tolerance and Asymmetrical Crosstolerance to Effects of the Indole Quinuclidinone Analog PNR-4-20, a G Protein-Biased Cannabinoid 1 Receptor Agonist in Mice: Comparisons with ?9-Tetrahydrocannabinol and JWH-018. J Pharmacol Exp Ther. 2019 05; 369(2):259-269.
    View in: PubMed
    Score: 0.049
  2. Glowa JR, Fantegrossi WE. Effects of dopaminergic drugs on food- and cocaine-maintained responding. IV: Continuous cocaine infusions. Drug Alcohol Depend. 1997 Apr 14; 45(1-2):71-9.
    View in: PubMed
    Score: 0.023
  3. Fantegrossi WE, Ullrich T, Rice KC, Woods JH, Winger G. 3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement. Psychopharmacology (Berl). 2002 Jun; 161(4):356-64.
    View in: PubMed
    Score: 0.023
  4. Fantegrossi WE, Ko MC, Woods JH, Richelson E. Antinociceptive, hypothermic, hypotensive, and reinforcing effects of a novel neurotensin receptor agonist, NT69L, in rhesus monkeys. Pharmacol Biochem Behav. 2005 Feb; 80(2):341-9.
    View in: PubMed
    Score: 0.023
  5. Fantegrossi WE, Kiessel CL, De la Garza R, Woods JH. Serotonin synthesis inhibition reveals distinct mechanisms of action for MDMA and its enantiomers in the mouse. Psychopharmacology (Berl). 2005 Sep; 181(3):529-36.
    View in: PubMed
    Score: 0.023
  6. Kalechstein AD, De La Garza R, Mahoney JJ, Fantegrossi WE, Newton TF. MDMA use and neurocognition: a meta-analytic review. Psychopharmacology (Berl). 2007 Jan; 189(4):531-7.
    View in: PubMed
    Score: 0.023
  7. Yarosh HL, Katz EB, Coop A, Fantegrossi WE. MDMA-like behavioral effects of N-substituted piperazines in the mouse. Pharmacol Biochem Behav. 2007 Nov; 88(1):18-27.
    View in: PubMed
    Score: 0.023
  8. Fantegrossi WE, Murnane KS, Reissig CJ. The behavioral pharmacology of hallucinogens. Biochem Pharmacol. 2008 Jan 01; 75(1):17-33.
    View in: PubMed
    Score: 0.023
  9. Fantegrossi WE. In vivo pharmacology of MDMA and its enantiomers in rhesus monkeys. Exp Clin Psychopharmacol. 2008 Feb; 16(1):1-12.
    View in: PubMed
    Score: 0.023
  10. Fantegrossi WE, Murai N, Math?na BO, Pizarro N, de la Torre R. Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine and its enantiomers in mice: pharmacokinetic considerations. J Pharmacol Exp Ther. 2009 Jun; 329(3):1006-15.
    View in: PubMed
    Score: 0.023
  11. Murnane KS, Murai N, Howell LL, Fantegrossi WE. Discriminative stimulus effects of psychostimulants and hallucinogens in S(+)-3,4-methylenedioxymethamphetamine (MDMA) and R(-)-MDMA trained mice. J Pharmacol Exp Ther. 2009 Nov; 331(2):717-23.
    View in: PubMed
    Score: 0.023
  12. Fantegrossi WE, Gannon BM, Zimmerman SM, Rice KC. In vivo effects of abused 'bath salt' constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity. Neuropsychopharmacology. 2013 Mar; 38(4):563-73.
    View in: PubMed
    Score: 0.023
  13. Seely KA, Patton AL, Moran CL, Womack ML, Prather PL, Fantegrossi WE, Radominska-Pandya A, Endres GW, Channell KB, Smith NH, McCain KR, James LP, Moran JH. Forensic investigation of K2, Spice, and "bath salt" commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Sci Int. 2013 Dec 10; 233(1-3):416-22.
    View in: PubMed
    Score: 0.023
  14. Tai S, Hyatt WS, Gu C, Franks LN, Vasiljevik T, Brents LK, Prather PL, Fantegrossi WE. Repeated administration of phytocannabinoid ?(9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner. Pharmacol Res. 2015 Dec; 102:22-32.
    View in: PubMed
    Score: 0.023
  15. Ford BM, Tai S, Fantegrossi WE, Prather PL. Synthetic Pot: Not Your Grandfather's Marijuana. Trends Pharmacol Sci. 2017 03; 38(3):257-276.
    View in: PubMed
    Score: 0.023
  16. Gannon BM, Fantegrossi WE. Cocaine-Like Discriminative Stimulus Effects of Mephedrone and Naphyrone in Mice. J Drug Alcohol Res. 2016; 5.
    View in: PubMed
    Score: 0.023
  17. Berquist MD, Hyatt WS, Bauer-Erickson J, Gannon BM, Norwood AP, Fantegrossi WE. Phencyclidine-like in?vivo effects of methoxetamine in mice and rats. Neuropharmacology. 2018 05 15; 134(Pt A):158-166.
    View in: PubMed
    Score: 0.023
  18. Patton AL, Seely KA, Yarbrough AL, Fantegrossi W, James LP, McCain KR, Fujiwara R, Prather PL, Moran JH, Radominska-Pandya A. Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants. Biochem Biophys Res Commun. 2018 04 06; 498(3):597-602.
    View in: PubMed
    Score: 0.023
  19. Jones S, Yarbrough AL, Fantegrossi WE, Prather PL, Bush JM, Radominska-Pandya A, Fujiwara R. Identifying cytochrome P450s involved in oxidative metabolism of synthetic cannabinoid N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135). Pharmacol Res Perspect. 2020 02; 8(1):e00561.
    View in: PubMed
    Score: 0.023
  20. Crosby SV, Ahmed IY, Osborn LR, Wang Z, Schleiff MA, Fantegrossi WE, Nagar S, Prather PL, Boysen G, Miller GP. Similar 5F-APINACA Metabolism between CD-1 Mouse and Human Liver Microsomes Involves Different P450 Cytochromes. Metabolites. 2022 Aug 22; 12(8).
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.